XNCR - Xencor, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Xencor, Inc.
Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers.
IPO Date: December 3, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $1.8B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.58 | 2.53%
Avg Daily Range (30 D): $0.83 | 3.19%
Avg Daily Range (90 D): $0.71 | 3.56%
Institutional Daily Volume
Avg Daily Volume: .3M
Avg Daily Volume (30 D): 1.02M
Avg Daily Volume (90 D): .87M
Trade Size
Avg Trade Size (Sh.): 67
Avg Trade Size (Sh.) (30 D): 66
Avg Trade Size (Sh.) (90 D): 60
Institutional Trades
Total Institutional Trades: 3,511
Avg Institutional Trade: $2.07M
Avg Institutional Trade (30 D): $4.16M
Avg Institutional Trade (90 D): $3.5M
Avg Institutional Trade Volume: .09M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.39M
Avg Closing Trade (30 D): $10.52M
Avg Closing Trade (90 D): $6.01M
Avg Closing Volume: 100.7K
 
News
Feb 18, 2026 @ 4:00 PM
CTLA-4 Inhibitors Competitive Landscape Research R...
Source: Researchandmarkets.Com
Jan 14, 2026 @ 8:30 AM
[Latest] Global T-Cell Engagers Market Size/Share ...
Source: Custom Market Insights
Aug 6, 2025 @ 8:13 PM
Xencor (XNCR) Q2 Revenue Jumps 82%
Source: Not Specified
Jul 16, 2025 @ 4:30 AM
[Latest] Global Ultomiris Drug Market Size/Share W...
Source: Custom Market Insights
Sep 12, 2024 @ 5:09 PM
Xencor Surges 10.5%: Is This an Indication of Furt...
Source: Zacks
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-2.16 $-.29 $-1.71
Diluted EPS $-2.16 $-.29 $-1.71
Revenue $104.97M $51.22M $4.52M
Gross Profit
Net Income / Loss $-163.33M $-21.73M $-128.92M
Operating Income / Loss $-216.08M $-37.07M $-77.86M
Cost of Revenue
Net Cash Flow $.13M $30.49M $-40M
PE Ratio